Dr. GPCR Podcast

Stuart graduated from the University of Leeds in the U.K. with a First Class Honors degree in Pharmacology. At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar.

Following his Ph.D., Dr. Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz at Duke University. Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor Biology Section at the Medical Research Council (MRC) -Human Reproductive Sciences Unit within the University of Edinburgh. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional signaling. To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns Hopkins University Medical Center. At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award, one of the few awards available within the intramural NIH program. Upon starting a new family, and returning to Europe, Dr. Maudsley continued his scientific journey with the award of the highly-valued Odysseus Program Type I Program Grant to work as both the Adjunct Director of the VIB Center for Molecular Neurology and also Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp.

Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases based on their gerontological underpinnings. This research stream is now forming the basis of a new technology-based start-up company, HeptOME, to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

After obtaining a BSc in chemistry at the University of Alberta in Edmonton Canada, Terry received his Ph.D. in Pharmacology from the University of Alberta, Department of Chemistry, Canada. Dr. Kenakin then moved to the UK, where he did a post-doctoral fellowship in University College London with Sir James Black.

His next stop took him to Burroughs-Wellcome (BW) in Research Triangle Park (RTP) in North Carolina USA. After 7 years at BW, Dr. Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome, and finally GlaxoSmithKline.

Since 2011,  Terry works at the Department of Pharmacology at the University of North Carolina School of Medicine Chapel Hill NC. His interests are in receptor pharmacology, allosteric protein function, and drug discovery.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Dr. Bender completed his undergraduate studies at Colgate University in upstate New York with a degree in Biochemistry. Between undergraduate and graduate school Brian worked as a technician in an academic lab before moving to Nashville, TN for graduate work at Vanderbilt University where he joined the Department of Pharmacology. Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. He then moved to the University of California in San Francisco to continue his training as a postdoctoral researcher where he used structural models of GPCRs to virtually screen large compound libraries with the goal of finding new chemical matter to probe understudied and orphan receptors.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Dr. Kathryn E Livingston is currently a Product Manager at Gator Bio, a biotechnology company providing solutions to researchers studying protein-protein interactions. Kathryn obtained her BS in Chemistry from Carnegie Mellon University and went on to receive a Ph.D. in Pharmacology at the University of Michigan. Working under the supervision of Dr. John Traynor, Kathryn worked to develop and understand first-in-class allosteric modulators of opioid receptors. Research into their mechanism of action in purified systems formed the base of her thesis work. Following this, Kathryn did a post-doctoral fellowship at UCSF in the laboratory of Dr. Mark von Zastrow. There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity in intact cellular systems. Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation, novel methods, or novel communication.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Alexander is currently a postdoc as a member of the personalized medicine cluster in Copenhagen and at the Institute of Biological Psychiatry in Roskilde working with the UK Biobank and other large-scale population cohorts.

Alexander has a big interest in the integration of large biomedical data in genomics, structural biology, pharmacology, and pharmacoepidemiology with innovative computational methods to gain novel insights into receptor biology.

During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen, he worked on novel analytical methods to identify human signaling systems and thereby discovered endogenous peptides activating several orphan receptors. Alexander had a research sabbatical with Madan Babu at the MRC Laboratory of Molecular Biology in Cambridge, UK, where he was working on the impact of genetic variations on drug response. He received the “HC Ørsted Research talent prize” and “Bayer Pharmaceuticals Ph.D. Award” for his work on GPCRs.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the University of Kent, United Kingdom. He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class B GPCRs as part of his postdoctoral training.

Today, Sam is a pharmacology data analyst and the founder of Pharmechanics LLC, a consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics and the understanding of receptor systems. As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics, particularly GPCR antagonists.

Before founding Pharmechanics in 2016, Dr. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences. He guided the in vitro biology efforts of the company for numerous drug discovery campaigns. Sam is known for demystifying complicated and newly-emerging pharmacology concepts, enabling them to be applied by project teams in optimizing new molecules.

I very much enjoyed chatting with Sam about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal.

Following his Ph.D. in Neurological Sciences at the same university in 1985, he completed a post-doctoral fellow at Duke University in the laboratory of R.R. Lefkowitz. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Council of Canada at the Faculty of Medicine of the Université de Montréal.

Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. Dr. Bouvier is the author of 300 scientific papers and 15 patents and delivered close to 500 invited conferences. He is a world-renowned expert in the field of cell signaling and GPCRs and made seminal contributions to our understanding of this major class of drug targets. In addition to paradigm shifts including inverse agonism, biased signaling, and pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery.

His work received more than 30,000 citations yielding an h-index of 95. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows. Michel’s scientific contributions were recognized by the attribution of many awards and distinctions including his election as a fellow of the Royal Society of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics (2017), the Wilder Penfield award from the Quebec Government (2017), the innovation award of ADRIQ (2019) and the 2021 Killam prize form the Canada Council for the Arts.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

''Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers, Squibb Co. in Lawrenceville, NJ. He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing his postdoctoral training at Northwestern University. He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility. He currently leads a team that provides mechanistic understanding of small molecule drug candidates across the entire portfolio of BMS. Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular, biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems.

Dr. Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has been an early champion of signaling bias as a physiological mechanism of gonadotropin action. He continues to pioneer in drug discovery studying GPCRs and other target classes. His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics is available on Amazon.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers, Squibb Co. in Lawrenceville, NJ. He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing his postdoctoral training at Northwestern University. He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility. He currently leads a team that provides a mechanistic understanding of small molecule drug candidates across the entire portfolio of BMS. Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular, biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems.

Dr. Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has been an early champion of signaling bias as a physiological mechanism of gonadotropin action. He continues to pioneer in drug discovery studying GPCRs and other target classes. His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics is available on Amazon.

I sat down with Brian to chat about GPCRs, working in the industry, and being a leader. This is part 1 of our conversation.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/

David Gloriam is a Professor in Computational Receptor Biology at the University of Copenhagen where he leads a research cluster for GPCR function and drug discovery and a Pharmaceutical Data Science unit. His group runs the GPCRdb database where ~4,000 researchers each month retrieve reference data and access online tools for analysis, visualization, and experiment design.

Dr. Gloriam is a corresponding member of the Nomenclature Committee of the International Union of Pharmacology (IUPHAR). He is one of the coordinators of recommendations to describe ligand bias towards signaling probes and safer drugs. His group recently developed an online resource of biased ligands and pathway effects to advance the biased signaling field.

Join me a learn more about David’s work, his career trajectory, and GPCRdb.

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Bring in a #GPCR Consultant

http://www.drgpcr.com/consulting/

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-   Become a #DrGPCR Ecosystem Member

http://www.drgpcr.com/membership/